The current understanding of Myasthenia Gravis has improved in recent decades, leading to growing awareness, improved management, and better outcomes. As per DelveInsight, the Myasthenia Gravis therapeutics market is anticipated to evolve immensely in the coming years owing to the launch of upcoming therapies and the rise in the number of cases of Myasthenia Gravis.
Several major pharma and biotech giants are working robustly on developing many new therapies for MG, such as Firdapse (Catalyst Pharmaceuticals); Hizentra (CSL Behring); Rozanolixizumab (UCB Pharma); Efgartigimod (Argenx); Zilucoplan (Ra Pharmaceuticals); Ravulizumab (Alexion Pharmaceuticals); IMVT-1401 (Immunovant); M281 (Momenta Pharmaceuticals), TAK-079 (Takeda) and others. The pipeline is crowded, with several potential therapies with the imminent attention of big pharmaceutical companies for this market space.
“Myasthenia Gravis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Myasthenia Gravis Market.
The Myasthenia Gravis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Myasthenia Gravis Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Myasthenia Gravis and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Myasthenia Gravis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Myasthenia Gravis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Infusion
-
Intradermal
-
Intramuscular
-
Intranasal
-
Intravaginal
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
Molecule Type
Products have been categorized under various Molecule types, such as
-
Vaccines
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
Mechanism of Action of the Emerging Pipeline Therapies
-
Complement C5 inhibitor
-
Antibody-dependent cell cytotoxicity; T lymphocyte stimulant
-
Acetylcholinesterase inhibitor
-
Immunologic cytotoxicity; T lymphocyte replacement
-
Chloride channel antagonists
-
CCR5 receptor antagonist
-
Complement factor D inhibitor
-
Acetylcholine inhibitor
-
Neonatal Fc receptor antagonist
Learn How the Ongoing Clinical & Commercial Activities will Affect the Myasthenia Gravis Therapeutic Segment @
https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight
Myasthenia Gravis Therapeutics Landscape
Several major pharma and biotech companies are developing therapies for Myasthenia Gravis. Currently, Argenx is leading the therapeutics market with its Myasthenia Gravis drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Myasthenia Gravis Therapeutics Market Include:
Ahead Therapeutics, Alexion Pharmaceuticals, Argenx, Cabaletta Bio, Cartesian Therapeutics, Catalyst Pharmaceuticals, CSL Behring, CytoDyn, DAS Therapeutics, Harbour BioMed, Hoffmann-La Roche, Horizon Therapeutics, Momenta Pharmaceuticals, Nanjing IASO Biotherapeutics, Novartis, Ra Pharmaceuticals, Rallybio, Regeneron Pharmaceuticals, RemeGen, Sanofi, Takeda, Toleranzia, UCB Pharma, Viela Bio, and others.
Myasthenia Gravis Emerging and Marketed Drugs Covered in the Report Include:
-
DAS-001: DAS Therapeutics
-
Descartes-08: Cartesian Therapeutics
-
Efgartigimod: Argenx
-
Firdapse: Catalyst Pharmaceuticals
-
Hizentra: CSL Behring
-
Inebilizumab: Horizon pharma
-
Inebilizumab: Horizon Therapeutics
-
MuSK-CAART: Cabaletta Bio
-
Ravulizumab: Alexion Pharmaceuticals
-
RLYB116: Rallybio
-
Rozanolixizumab: UCB Biopharma
-
TAK-079:Takeda
-
Zilucoplan: Ra Pharmaceuticals
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Myasthenia Gravis Current Treatment Patterns
4. Myasthenia Gravis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Myasthenia Gravis Late Stage Products (Phase-III)
7. Myasthenia Gravis Mid-Stage Products (Phase-II)
8. Myasthenia Gravis Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Myasthenia Gravis Discontinued Products
13. Myasthenia Gravis Product Profiles
14. Key Companies in the Myasthenia Gravis Market
15. Key Products in the Myasthenia Gravis Therapeutics Segment
16. Dormant and Discontinued Products
17. Myasthenia Gravis Unmet Needs
18. Myasthenia Gravis Future Perspectives
19. Myasthenia Gravis Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/